Reshape Lifesciences (NASDAQ: RSLS) is one of 66 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare Reshape Lifesciences to similar companies based on the strength of its earnings, profitability, institutional ownership, dividends, risk, analyst recommendations and valuation.
This table compares Reshape Lifesciences and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Reshape Lifesciences Competitors||-169.90%||-24.43%||-9.12%|
Reshape Lifesciences has a beta of 2.98, meaning that its share price is 198% more volatile than the S&P 500. Comparatively, Reshape Lifesciences’ competitors have a beta of 0.86, meaning that their average share price is 14% less volatile than the S&P 500.
Institutional and Insider Ownership
0.8% of Reshape Lifesciences shares are held by institutional investors. Comparatively, 52.5% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 26.4% of Reshape Lifesciences shares are held by company insiders. Comparatively, 17.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a summary of current recommendations and price targets for Reshape Lifesciences and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Reshape Lifesciences Competitors||269||1699||3136||104||2.59|
Reshape Lifesciences presently has a consensus target price of $11.03, indicating a potential upside of 645.27%. As a group, “Advanced Medical Equipment & Technology” companies have a potential upside of 0.91%. Given Reshape Lifesciences’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Reshape Lifesciences is more favorable than its competitors.
Valuation and Earnings
This table compares Reshape Lifesciences and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Reshape Lifesciences||$790,000.00||-$23.36 million||-0.25|
|Reshape Lifesciences Competitors||$2.23 billion||$238.72 million||-99.56|
Reshape Lifesciences’ competitors have higher revenue and earnings than Reshape Lifesciences. Reshape Lifesciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Reshape Lifesciences competitors beat Reshape Lifesciences on 7 of the 13 factors compared.
About Reshape Lifesciences
ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
Receive News & Ratings for Reshape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reshape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.